Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 25;12:8897. doi: 10.1038/s41598-022-12930-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Lipidomic analysis of plasma and cardiac tissue samples from animals treated with serelaxin. (A,B) S1P levels are significantly higher in cardiac tissue and plasma samples extracted from animals receiving chronic serelaxin treatment. No significant differences were observed in sphingosine (So), dihydrosphingosine (DHSo), and dihydro S1P (DHS1P) levels in either cardiac tissue or plasma samples with treatment. For (A,B) unpaired T-test was performed within data sets of the same type. (C) Analysis of plasma ceramides (treated vs. untreated) shows significantly higher levels of C24:0 (P = 0.000006), C24:1 (P = 0.000008), C16:0 (P = 0.000011), and C22:0 (P = 0.0023) ceramides in extracts from serelaxin treated mice; (D) Plasma ceramide 1-Phosphate (C1P) levels are significantly higher in serelaxin treated mice, achieving significance in C22:0 (P < 0.0013), C18:1 (P = 0.0099) and C18:0 (P = 0.014) C1P levels. For A and B, n = 6 for vehicle, and n = 9 for serelaxin treated mice. For (C,D) unpaired T-test was used for comparisons. (E,F) Plasma and cardiac levels of S1P were not significantly lower with daily, i.p. injections of PF543 dissolved in the amphiphilic solvent Kolliphor HS 15.